Search

Displaying results 8171 - 8180 of 8691 in total
  1. Drug

    FP-1096

    go.drugbank.com/drugs/DB05310
    Experimental

    FP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.

  2. Drug

    Cinolazepam

    go.drugbank.com/drugs/DB01594
    Investigational

    Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.

  3. Drug

    AZD-9684

    go.drugbank.com/drugs/DB05712
    Experimental

    AZD-9684 is the first member of a new anti-thrombotic class (CPU inhibitors). It is being developed by AstraZeneca.

  4. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology. It provides patients with long term therapeutic benefit from a single administrat...

  5. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  6. Drug

    MAHDL01

    go.drugbank.com/drugs/DB06270
    Experimental

    MAHDL01 is a pharmaceutical combination of whole plants, which is used to increase the HDL/LDL ratio that improves overall cardiovascular health.

  7. Drug

    Semuloparin

    go.drugbank.com/drugs/DB06294
    Investigational

  8. Drug

    R107474

    go.drugbank.com/drugs/DB06553
    Experimental

  9. Drug

    P-57AS3

    go.drugbank.com/drugs/DB06569
    Experimental

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Gantacurium

    go.drugbank.com/drugs/DB05710
    Investigational

    Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.